If this is the year you are planning to replace your sound processor with next-generation technology, it’s time to get started. Especially if you’re planning to use your 2018 insurance benefits, we recommend placing all orders by October 29, 2018.
There are significant advancements in next-generation Cochlear™ Nucleus® and Baha® Sound Processors. New features stream sound wirelessly from everyday devices—such as phones, tablets and TVs—and let you manage features with a smartphone app.
To help you answer important questions about insurance coverage and how to navigate the insurance process, Cochlear is pleased to announce the Insurance Support Center. Here, you’ll find:
- Three ways to pay: Step-by-step guides to self-pay, self-pay and seek reimbursement on your own, and how to use Cochlear Reimbursement and Insurance Services.
- The complete list of Healthcare Common Procedure Coding System (HCPCS) codes. These are the codes insurance companies use to identify and confirm coverage of Cochlear hearing sound processors, parts and accessories.
- An up-to-date list of insurance plans where Cochlear is designated in-network.*
- Answers to frequently asked questions related to insurance coverage—including how to approach a denial.
- Downloadable forms for U.S. and Canadian recipients to order next generation Nucleus and Baha Sound Processors.
*Don’t forget: If your insurance plan does not include Cochlear within its network of providers, we may need to obtain an in-network exception. An in-network or network gap exception is a tool health insurance companies use to compensate for gaps in their network of contracted health-care providers. Because Cochlear is the only health-care provider of the sound processor that is compatible with your implant, your insurance company needs to be informed that this technology cannot be obtained elsewhere.
Cochlear is actively working on additional insurance plan contracts to expand coverage of medically necessary technology. We recommend patients submit a request-to-contract form directly to their insurance plans as plans are more inclined research Cochlear medical efficacy when they hear from their plan participants.